Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-01-06 @ 7:19 AM
Study NCT ID:
NCT03194893
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-25
First Post:
2017-06-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-07-05
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-30
Completion Date Type:
ESTIMATED
First Submit Date:
2017-06-20
First Submit QC Date:
None
Study First Post Date:
2017-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-21
Last Update Post Date:
2025-11-25
Last Update Post Date Type:
ESTIMATED